Bris­tol My­er­s' Op­di­vo keeps can­cer at bay in more lym­phoma pa­tients than Seagen's Ad­cetris in PhI­II: #AS­CO23

CHICA­GO — In a study pit­ting Seagen’s Ad­cetris against Bris­tol My­ers Squibb’s Op­di­vo in new­ly di­ag­nosed pa­tients with ad­vanced clas­sic Hodgkin lym­phoma, a greater pro­por­tion of those who re­ceived Op­di­vo saw no can­cer growth at one year com­pared to those who got Ad­cetris.

In ad­di­tion, pa­tients in the Op­di­vo arm of the Phase III tri­al re­port­ed re­duced tox­i­c­i­ties, ac­cord­ing to lead in­ves­ti­ga­tor Alex Her­rera, a hema­tol­o­gist-on­col­o­gist at City of Hope’s can­cer can­cer in Duarte, CA. No­tably, the tri­al in­clud­ed more than 200 chil­dren across both arms. Gen­er­al­ly, more than half of chil­dren with ad­vanced Hodgkin lym­phoma re­ceive ra­di­a­tion ther­a­py, but in this tri­al, dubbed SWOG S1826, on­ly a hand­ful of pa­tients in the two arms re­ceived ra­dio­ther­a­py, spar­ing many chil­dren from long-term side ef­fects of ra­di­a­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.